Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
MWN-AI** Summary
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), based in Lexington, Massachusetts, has announced a significant follow-on multi-system order from Samsung Biologics aimed at expanding the deployment of its Growth Direct platform. This advancement underscores the strong collaboration between the two companies, with Samsung Biologics leveraging the Growth Direct system to enhance automated microbial quality control (MQC) across its manufacturing operations.
The Growth Direct platform is designed to modernize traditional MQC testing workflows, which have historically been labor-intensive. By automating these processes, Rapid Micro Biosystems delivers faster results, improved accuracy, and better data integrity, facilitating a more efficient production environment for vital healthcare products, including biologics and vaccines. Robert Spignesi, President and CEO of the Company, emphasized the importance of this partnership, highlighting Samsung's advanced automation and digital capabilities that contribute to high productivity and quality in their manufacturing practices.
With this new order, Rapid Micro Biosystems is positioned to support Samsung as it scales its innovative manufacturing operations, which are increasingly reliant on automation for quality control. The inclusion of Growth Direct systems into Samsung’s integrated plant design exemplifies a commitment to leveraging cutting-edge technology in biopharmaceutical production.
Rapid Micro Biosystems has established a strong foundation in the life sciences sector, with operations extending beyond the U.S. to include sites in Switzerland, Germany, and the Netherlands. The company remains focused on pushing technological boundaries in healthcare product manufacturing, enhancing efficiency, compliance, and rapid decision-making for its clients.
Investors and stakeholders interested in further details about the Growth Direct platform can explore more through Rapid Micro Biosystems' official communications and website.
MWN-AI** Analysis
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) has recently announced a significant multi-system order from Samsung Biologics, marking a pivotal moment in their partnership. This follows the growing trend of automation in the life sciences sector, highlighting the increasing reliance on innovative technologies for microbial quality control, especially in pharmaceutical manufacturing.
Investors should view this announcement as a bullish indication for Rapid Micro Biosystems' growth trajectory. The company's flagship Growth Direct platform is designed to replace antiquated manual microbial quality control workflows, thereby enhancing operational efficiency and data integrity—a critical concern in the highly regulated biotech industry. As Samsung Biologics expands its operations, the enhanced deployment of Growth Direct suggests a strong demand for Rapid's technology and a solid validation of its value proposition.
In terms of market positioning, Rapid Micro appears well-placed as a leader in automated solutions, particularly as CDMOs (Contract Development and Manufacturing Organizations) become increasingly important in the biopharmaceutical supply chain. The focus on faster results and enhanced accuracy in quality control is particularly relevant in today’s landscape, where the speed of product rollout can impact market share significantly.
However, investors should also be mindful of the risks associated with forward-looking statements. The company faces challenges such as competition, supply chain stability, and regulatory compliance. Engaging with these uncertainties will be paramount for stakeholders assessing the future trajectory of RPID stock.
In summary, the latest developments with Samsung Biologics provide a strong case for considering an investment in Rapid Micro Biosystems. The potential for growth in automation within life sciences, coupled with the company's established reputation, positions it as a compelling opportunity in an evolving market landscape. Investors should weigh the positive implications against the inherent risks as they evaluate their positions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced a new multi-system order from Samsung Biologics for its Growth Direct platform.
This follow-on order builds on the companies’ existing partnership and supports Samsung’s continued expansion of the Growth Direct platform to automate microbial quality control across its manufacturing network.
“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and we’re pleased to strengthen our partnership with this new multi-system order,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “Their integrated plant design embeds advanced automation and digitalization capabilities, including seamless connectivity across operations - to consistently deliver high productivity and quality. The Growth Direct platform enhances that foundation by delivering faster time to results, greater accuracy, and stronger data integrity. We look forward to supporting Samsung as it continues scaling its next-generation manufacturing operations.”
To learn more about the Company and the Growth Direct platform please visit: Rapid Micro Biosystems.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit?www.rapidmicrobio.com?or follow the Company on X (formerly known as Twitter) at?@rapidmicrobio?or on?LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the expanded deployment of the Company’s Growth Direct platform.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; competition within the Company’s industry; the Company’s ability to maintain its manufacturing operations; risks related to third-parties; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility on the Company’s business and operations; and the other important factors outlined under the caption “Risk Factors” in the Company’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 7, 2025, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Rapid Micro Biosystems Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Rapid Micro Biosystems Media Contact: media@rapidmicrobio.com
FAQ**
How does the new multi-system order from Samsung Biologics enhance Rapid Micro Biosystems Inc. RPID's position in the automated microbial quality control market, and what specific benefits are expected from the Growth Direct platform?
What metrics or benchmarks will Rapid Micro Biosystems Inc. RPID use to evaluate the success of its partnership with Samsung Biologics following this multi-system order?
Considering the potential risks mentioned in the press release, what strategies does Rapid Micro Biosystems Inc. RPID have in place to mitigate these risks and maintain its competitive edge in the life sciences technology sector?
How does Rapid Micro Biosystems Inc. RPID plan to leverage its advancements in automation and digitalization capabilities to further expand its market presence and support its clients in the evolving healthcare manufacturing landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Rapid Micro Biosystems Inc. (NASDAQ: RPID).
NASDAQ: RPID
RPID Trading
3.31% G/L:
$2.34 Last:
156,211 Volume:
$2.28 Open:
